Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 10/20 | 0.57 |
| ▸ | MRGPRX1 | Q96LB2 | 5/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.45 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.44 |
| ▸ | EPAS1 | Q99814 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16335383 | 0.96 | BRD4 (0.54) | BRD4MRGPRX1KDM4EMAPK14EPAS1 | |
| Ethane SCHEMBL16335382 | 0.96 | BRD4 (0.54) | BRD4MRGPRX1KDM4EMAPK14EPAS1 | |
| SCHEMBL15067364 | 0.90 | BRD4 (0.58) | BRD4MRGPRX1KDM4EMAPK14EPAS1 | |
| SCHEMBL16335277 | 0.89 | BRD4 (0.59) | BRD4MRGPRX1KDM4EMAPK14EPAS1 | |
| SCHEMBL16335525 | 0.87 | BRD4 (0.55) | BRD4MRGPRX1MAPK14EPAS1 | |
| SCHEMBL28718898 | 0.84 | EPAS1 (0.47) | BRD4MRGPRX1MAPK14EPAS1 | |
| SCHEMBL29549178 | 0.84 | EPAS1 (0.47) | BRD4MRGPRX1MAPK14EPAS1 | |
| SCHEMBL16335784 | 0.83 | BRD4 (0.56) | BRD4MRGPRX1MAPK14EPAS1 | |
| SCHEMBL16334849 | 0.83 | BRD4 (0.62) | BRD4MRGPRX1ALDH1A1HPGD | |
| SCHEMBL29549377 | 0.83 | BRD4 (0.51) | BRD4MRGPRX1MAPK14EPAS1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230158039-A1 | BROMODOMAIN INHIBITORS | ABBVIE INC (US) | 2023-05-25 | — | — | US | disclosed |
| US-20210236508-A1 | BROMODOMAIN INHIBITORS | ABBVIE INC (US) | 2021-08-05 | — | — | US | disclosed |
| CN-106986872-B | Bromodomain inhibitors | 艾伯维公司 | 2020-04-21 | — | — | CN | disclosed |
| US-20190084981-A1 | Bromodomain Inhibitors | ABBVIE INC (US) | 2019-03-21 | — | — | US | disclosed |
| US-10131657-B2 | Bromodomain inhibitors | ABBVIE INC. (US) | 2018-11-20 | — | — | US | disclosed |
| US-20180296566-A1 | BROMODOMAIN INHIBITORS | ABBVIE INC (US) | 2018-10-18 | — | — | US | disclosed |
| US-9957263-B2 | Bromodomain inhibitors | ABBVIE INC. (US) | 2018-05-01 | — | — | US | disclosed |
| EP-2797918-B1 | BROMODOMAIN INHIBITORS | ABBVIE INC (US) | 2017-11-29 | — | — | EP | disclosed |
| US-20160272630-A1 | Bromodomain Inhibitors | ABBVIE INC. (US) | 2016-09-22 | — | — | US | disclosed |
| US-20160185769-A1 | Bromodomain Inhibitors | ABBVIE INC. (US) | 2016-06-30 | — | — | US | disclosed |
| US-20160143916-A1 | BROMODOMAIN INHIBITORS | ABBVIE INC (US) | 2016-05-26 | — | — | US | disclosed |
| US-9296741-B2 | Bromodomain inhibitors | ABBVIE INC. (US) | 2016-03-29 | — | — | US | disclosed |
| EP-2797918-A1 | BROMODOMAIN INHIBITORS | AbbVie Inc. (US) | 2014-11-05 | — | — | EP | disclosed |
| US-20140162971-A1 | BROMODOMAIN INHIBITORS | ABBVIE INC. | 2014-06-12 | — | — | US | disclosed |
| WO-2013097601-A1 | BROMODOMAIN INHIBITORS | ABBVIE INC. (US) | 2013-07-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180296566-A1 | BROMODOMAIN INHIBITORS | BRD4, BRD1, BRD3 | BRD4 1/4885MRGPRX1 150/4885KDM4E 988/4885 |
| US-20190084981-A1 | Bromodomain Inhibitors | BRD4, BRD1, BRD3 | BRD4 1/4885MRGPRX1 302/4885KDM4E 749/4885 |
| US-20140162971-A1 | BROMODOMAIN INHIBITORS | BRD4, BRD1, BRD3 | BRD4 1/4885MRGPRX1 150/4885KDM4E 988/4885 |
| US-10131657-B2 | Bromodomain inhibitors | BRD1, BRD4, BRD3 | BRD4 2/4885MRGPRX1 241/4885KDM4E 834/4885 |
| US-20160272630-A1 | Bromodomain Inhibitors | BRD4, BRDT, EP300 | BRD4 1/4885MRGPRX1 703/4885KDM4E 1675/4885 |
| US-20230158039-A1 | BROMODOMAIN INHIBITORS | BRD4, BRD1, BRD3 | BRD4 1/4885MRGPRX1 150/4885KDM4E 988/4885 |
| US-20160185769-A1 | Bromodomain Inhibitors | BRD1, BRD4, BRD3 | BRD4 2/4885MRGPRX1 241/4885KDM4E 834/4885 |
| US-20160143916-A1 | BROMODOMAIN INHIBITORS | BRD4, BRD1, BRD3 | BRD4 1/4885MRGPRX1 150/4885KDM4E 988/4885 |
| US-20210236508-A1 | BROMODOMAIN INHIBITORS | BRD4, BRD1, BRD3 | BRD4 1/4885MRGPRX1 150/4885KDM4E 988/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.